公开(公告)号：US11654105B2

公开(公告)日：2023-05-23

申请号：US17821426

申请日：2022-08-22

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Ali Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  A61K39/395 ,  A61K9/08 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  A61K47/20 ,  A61K39/00 ,  A61P35/00 ,  A61K38/47

CPC classification number: A61K9/0019 ,  A61K9/08 ,  A61K38/47 ,  A61K39/001106 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/20 ,  A61K47/26 ,  A61P35/00 ,  C07K16/32 ,  C12Y302/01035 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/585 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/90

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US10849849B2

公开(公告)日：2020-12-01

申请号：US15872648

申请日：2018-01-16

Applicant: Genentech, Inc. ,  F. Hoffmann-La Roche AG

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  A61K39/395 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  A61K47/20 ,  A61K39/00 ,  A61P35/00 ,  A61K9/08 ,  A61K38/47

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US20230092354A1

公开(公告)日：2023-03-23

申请号：US17821426

申请日：2022-08-22

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Ali Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: A61K9/00 ,  C07K16/32 ,  A61K47/18 ,  A61K47/26 ,  A61K39/395 ,  A61K47/20 ,  A61K39/00 ,  A61P35/00 ,  A61K9/08 ,  A61K38/47

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US10653779B2

公开(公告)日：2020-05-19

申请号：US14207901

申请日：2014-03-13

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Mary Mallaney ,  Parbir Grewal

IPC: A61K39/395 ,  A61K47/22 ,  C07K16/00 ,  A61K47/18 ,  C07K16/28

Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.

公开(公告)号：US20180296470A1

公开(公告)日：2018-10-18

申请号：US15872648

申请日：2018-01-16

Applicant: Genentech, Inc. ,  F. Hoffmann-La Roche AG

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: A61K9/00 ,  C07K16/32 ,  A61K9/08 ,  A61K38/47 ,  A61P35/00

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US20160175438A1

公开(公告)日：2016-06-23

申请号：US15058520

申请日：2016-03-02

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Lukas C. Amler ,  Mark C. Benyunes ,  Emma L. Clark ,  Christina H. de Toledo Pelizon ,  Zephania W. Kwong Glover ,  Lada Mitchell ,  Jayantha Ratnayake ,  Graham A. Ross ,  Ru-Amir Walker

IPC: A61K39/395 ,  A61K31/337 ,  A61K45/06 ,  C07K16/32

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; and treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag.

Abstract translation: 本申请描述了一种同类别的HER2二聚抑制剂Pertuzumab的用途。 特别地，本申请描述了在HER2阳性乳腺癌患者群体中扩展无进展生存的方法; 结合两种HER2抗体治疗HER2阳性癌症而不增加心脏毒性; 并通过从相同的静脉内袋中共同施用Pertuzumab和曲妥珠单抗的混合物来治疗HER2阳性癌症。

公开(公告)号：US11596620B2

公开(公告)日：2023-03-07

申请号：US15821470

申请日：2017-11-22

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Mary Mallaney ,  Parbir Grewal

IPC: A61K31/405 ,  A61K39/395 ,  C07K16/28 ,  C07K16/24 ,  G01N33/68 ,  C12Q1/28 ,  A61K39/00

Abstract: The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation.

公开(公告)号：US20210085597A1

公开(公告)日：2021-03-25

申请号：US16952670

申请日：2020-11-19

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Jennifer Eng-Wong ,  Whitney Kirschbrown ,  Tarik Ali Khan ,  Jasper Lin ,  Sreedhara Alavattam ,  Amit Garg ,  Sarah Heeson ,  Tanja Badovinac-Crnjevic ,  Christine Wurth

IPC: A61K9/00 ,  C07K16/32 ,  A61K47/18 ,  A61K47/26 ,  A61K39/395 ,  A61K47/20 ,  A61K39/00 ,  A61P35/00 ,  A61K9/08 ,  A61K38/47

Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.

公开(公告)号：US20130195851A1

公开(公告)日：2013-08-01

申请号：US13723889

申请日：2012-12-21

Applicant: Genentech, Inc.

Inventor： Sreedhara Alavattam ,  Christina H. de Toledo Pelizon ,  Zephania Kwong Glover ,  Lada Mitchell

IPC: A61K39/42 ,  A61K39/395

CPC classification number: A61K39/42 ,  A61K39/3955 ,  A61K39/39558 ,  A61K39/39591 ,  A61K2039/507 ,  A61K2039/54 ,  C07K16/088 ,  C07K16/32 ,  A61K2300/00

Abstract: The present invention relates to articles of manufacture and methods for co-administration of antibodies and/or antibody-like molecules, and further concerns methods for intravenous administration of more than one antibody and/or antibody-like molecule to a subject in need from a stable mixture contained in the same article of manufacture, such as an intravenous infusion bag (IV bag).

Abstract translation: 本发明涉及用于共同给予抗体和/或抗体样分子的制品和方法，并且还涉及将一种以上抗体和/或抗体样分子静脉内施用于需要的受试者的方法 包含在同一制品中的稳定的混合物，例如静脉输液袋（IV袋）。

公开(公告)号：US20130095172A1

公开(公告)日：2013-04-18

申请号：US13649591

申请日：2012-10-11

Applicant: GENENTECH, INC.

Inventor： Sreedhara Alavattam ,  Lukas C. Amler ,  Mark C. Benyunes ,  Emma L. Clark ,  Christina H. de Toledo Pelizon ,  Zephania W. Kwong Glover ,  Lada Mitchell ,  Jayantha Ratnayake ,  Graham A. Ross ,  Ru-Amir Walker

IPC: A61K39/395 ,  A61P35/04 ,  A61P35/00 ,  C07K16/30 ,  A61K9/127

CPC classification number: A61K39/39558 ,  A61K31/337 ,  A61K45/06 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/32 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present application describes uses for and articles of manufacture including Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity; treating early-stage HER2-positive breast cancer; treating HER2-positive cancer by co-administering a mixture of Pertuzumab and Trastuzumab from the same intravenous bag; treating HER2-positive metastatic gastric cancer; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and Vinorelbine; treating HER2-positive breast cancer with Pertuzumab, Trastuzumab and aromatase inhibitor; and treating low HER3 ovarian, primary peritoneal, or fallopian tube cancer. It also describes an article of manufacture comprising a vial with Pertuzumab therein and a package insert providing safety and/or efficacy data thereon; a method of making the article of manufacture; and a method of ensuring safe and effective use of Pertuzumab related thereto. In addition the application describes an intravenous (IV) bag containing a stable mixture of Pertuzumab and Trastuzumab suitable for administration to a cancer patient.

Abstract translation: 本申请描述了包括Pertuzumab（一流的HER2二聚抑制剂）的用途和制品。 特别地，本申请描述了在HER2阳性乳腺癌患者群体中扩展无进展生存的方法; 结合两种HER2抗体治疗HER2阳性癌症而不增加心脏毒性; 治疗早期HER2阳性乳腺癌; 通过从相同的静脉内袋中共同施用Pertuzumab和曲妥珠单抗的混合物来治疗HER2阳性癌症; 治疗HER2阳性转移性胃癌; 用Pertuzumab，曲妥珠单抗和长春瑞滨治疗HER2阳性乳腺癌; 用Pertuzumab，曲妥珠单抗和芳香酶抑制剂治疗HER2阳性乳腺癌; 并治疗低HER3卵巢，原发性腹膜或输卵管癌。 它还描述了一种制造方法，其中包括其中具有Pertuzumab的小瓶和在其上提供安全性和/或功效数据的包装插页; 制造该制品的方法; 以及确保安全有效地使用与之相关的Pertuzumab的方法。 此外，本申请描述了一种静脉内（IV）袋，其中含有适用于给予癌症患者的Pertuzumab和曲妥珠单抗的稳定混合物。